In May 2026, Angelini Pharma announced its acquisition of Catalyst Pharmaceuticals for $4.1 billion USD ($31.50 per share) — a transaction that functioned less as a conventional bolt-on and more as a strategic repositioning signal. Angelini had built its pharmaceutical business on an established central nervous system franchise: branded psychiatry and neurology assets with deep payer relationships, established commercial infrastructure, and a field force optimized for a competitive but navigable market.
Catalyst brought a portfolio of already-approved rare neurological disease assets — Firdapse for Lambert-Eaton myasthenic syndrome, Agamree for Duchenne Muscular Dystrophy, and Fycompa for focal seizures — along with an established U.S. commercial infrastructure in the rare disease space. The acquisition was not a portfolio addition. It was a mechanism for bypassing the internal resource allocation dynamics that would have prevented Angelini from building a credible rare disease position organically, and for acquiring in months the U.S. commercial access that would have taken a decade to develop.
This is the strategic problem that Harvard Business School professor Clayton Christensen named — the innovator's dilemma — and that most organizations with successful legacy positions never solve: the forces that produce success in an established market make it nearly impossible to redirect resources toward the market that will eventually displace it. The legacy franchise generates revenue. The revenue funds the organization. The organization's capabilities, culture, and leadership attention have been built around sustaining the franchise.
Every resource allocation decision is informed by the returns available from continuing to invest in what is already working. The emerging opportunity — which requires different capabilities, lower near-term returns, and a willingness to underinvest in what currently sustains the organization — cannot compete for resources on these terms. It loses, quarter after quarter, not because the leadership team does not see it, but because the organizational machinery processes every resource request through the lens of existing commitments.
The gravitational mechanism
Christensen's innovator's dilemma is not primarily a failure of strategic vision. Most leaders in legacy positions can articulate the disruption that is approaching. The failure is structural: the governance processes, incentive systems, and resource allocation mechanisms that sustain performance in the existing market systematically disadvantage the investments required to build position in the emerging one. A new therapy area that targets a rare patient population with high development risk and a ten-year commercialization horizon cannot generate the near-term financial metrics that a mature branded franchise produces.
In a resource allocation process that evaluates investments against a shared set of financial hurdles, the rare disease program will consistently underperform the legacy asset until it is too late for the organization to build the capability required to be competitive in the space it missed.
W. Chan Kim and Renée Mauborgne's Blue Ocean framework provides a complementary lens that is particularly useful for legacy market analysis: when the primary dimensions of competition in a market have been imitated to the point where they no longer differentiate, the resources consumed in competing on those dimensions are generating declining returns relative to what those same resources could produce elsewhere.
The strategic canvas of a mature pharmaceutical franchise — efficacy profiles that are broadly comparable across branded competitors, access and pricing that has been eroded by formulary pressure, a sales force model that every competitor has replicated — reveals an investment that has become table stakes. The organization is spending heavily to maintain a position whose value is eroding, and the accounting of current revenue does not reveal the opportunity cost because it has no mechanism for displaying what the resources could have built instead.
What escaping gravity actually requires
The governance conditions that allow an organization to escape the gravity of a legacy market are specific and genuinely rare. They require, first, a leadership team that evaluates the legacy position against its future trajectory rather than its current performance — that can look at a profitable franchise with intact market position and conclude that the competitive forces acting on it make its future value lower than its current value suggests. This is the opposite of the analysis that most strategy processes are designed to produce, which is a forward projection of current performance adjusted for known risks.
They require, second, a strategy process that makes the opportunity cost of legacy investment explicit, comparable, and present in the room when the resource allocation decision is made. The pharmaceutical executive team that sees the legacy CNS franchise's ten-year projected revenue alongside the rare disease platform's ten-year projected value — including the probability-weighted scenarios in which the legacy franchise's position erodes to genericization while the rare disease portfolio builds durable competitive moat through orphan drug exclusivity — is making a different decision than the team that sees each asset evaluated in isolation against its own financial hurdle.
The comparison is uncomfortable precisely because it requires the advocates for the legacy position to defend its future value against an explicit alternative rather than against an abstract opportunity cost that the planning process never makes visible.
The acquisition logic — using an external transaction to force the repositioning — is often the most effective mechanism because it bypasses the internal advocacy dynamics that would otherwise prevent it. Once the transaction is complete, the resource implications follow necessarily from the strategic logic of the deal rather than from a governance process that can be relitigated. The organization that acquires its future has escaped the gravity of its past through the one mechanism that the internal machinery cannot reverse. The organizations that wait for the internal machinery to produce the same decision rarely get there in time.
Frequently Asked Questions
Why is exiting a successful legacy market harder than exiting a failing one?
Christensen's research on disruptive innovation identified the innovator's dilemma: the organizational forces that make incumbents successful in existing markets — responsiveness to current customers, resource allocation toward proven returns, capability development aligned with existing demands — are precisely the forces that make it difficult to pursue emerging opportunities that will eventually displace them.
A legacy market still generating revenue exerts a gravitational pull on resources and attention that a strategy document cannot overcome. The dilemma is that the organization must underinvest in its legacy market before market forces require it — and every internal signal at that moment is pointing in the wrong direction.
How does Blue Ocean Strategy apply to the decision to exit established competitive spaces?
Kim and Mauborgne's framework provides a diagnostic for legacy exit decisions: when a competitive space has become so contested that the primary driver of position is price, the conditions that originally made it attractive have been eroded by competitive imitation. The 'eliminate-reduce-raise-create' grid, applied to the strategic canvas of an established market, frequently reveals that the activities consuming the most resources have become table stakes — generating declining marginal returns. The value is making visible the opportunity cost of resources consumed in the legacy space, which current revenue accounting systematically obscures.
What governance conditions allow organizations to make genuine legacy market exit decisions?
They require a leadership team that evaluates the legacy position against its future trajectory rather than its current performance, a strategy process that makes opportunity cost explicit and comparable, and a facilitation structure that prevents legacy advocates from effectively vetoing the analysis. The acquisition logic — using an external transaction to accelerate repositioning — is often the most effective mechanism precisely because it bypasses the internal advocacy dynamics that would otherwise prevent the exit.